Clinical trials: Myeloproliferative Diseases
Chronic Myeloid Leukemia
STI571 ProspectIve RandomIzed Trial: SPIRIT
To test whether increasing the dose of imatinib or combining it with IFNalpha or ara-C increases the rate of molecular response (as measured by the decrease in BCR-ABL transcripts after 12 months of treatment) in patients with…
- Trial name
- SPIRIT (NCT00219739)
- Testing
- Imatinib mesylate 400 mg, Imatinib mesylate 600 mg, Imatinib 400 mg + Peg-Interferon
- Where
- France
- Volunteers
- 789 people
- Sponsor
- Poitiers University Hospital
Myelofibrosis, Moderate Thrombocytopenia
A Study of Selinexor Monotherapy in Subjects With JAK Inhibitor-naïve Myelofibrosis and Moderate Thrombocytopenia
The main purpose of this study is to evaluate the efficacy of selinexor in JAKi-naïve participants with myelofibrosis (MF) and with normal platelet counts or with mild to moderate thrombocytopenia based on spleen volume reduction…
- Conditions
- Myelofibrosis, Moderate Thrombocytopenia, Mild Thrombocytopenia
- Trial name
- SENTRY-2 (NCT05980806)
- Testing
- Selinexor 60 mg, Selinexor 40 mg, Ruxolitinib
- Where
- 70 sites in United States, Belgium and 17 more
- Volunteers
- 58 people
- Sponsor
- Karyopharm Therapeutics Inc
CML, Chronic Phase
Study to Assess Efficacy and Safety of Inecalcitol in Imatinib-Treated Residual Chronic Myeloid Leukaemia: INIM Study
To assess the efficacy of inecalcitol in combination with imatinib in CML patients with molecular residual disease on imatinib monotherapy.
- Trial name
- ICT10 (NCT02949570)
- Testing
- Inecalcitol
- Where
- France
- Volunteers
- 54 people
- Sponsor
- Hybrigenics Corporation
Leukemia, Acute Myeloid, Myelodysplastic Syndromes
A Study of MGD024 in Patients With Relapsed or Refractory Hematologic Malignancies
CP-MGD024-01 is a Phase 1, open-label, multi-center study of MGD024 as a single agent in participants with select blood cancers that have not responded to treatment with standard therapies or who have relapsed after treatment.
- Conditions
- Leukemia, Acute Myeloid, Myelodysplastic Syndromes, Classical Hodgkin Lymphoma, Leukemia, B-cell
- Trial name
- NCT05362773
- Testing
- MGD024
- Where
- 7 sites in United States
- Volunteers
- 130 people
- Sponsor
- MacroGenics
Chronic Myelomonocytic Leukemia
IMM01+Azacitidine VS Placebo +Azacitidine in Patients With Newly Diagnosed Chronic Myelomonocytic Leukemia (CMML1-2)
This study is a randomized, controlled, double-blind, multicenter, phase Ⅲ clinical study to evaluate the efficacy of IMM01(timdarpacept) in combination with azacitidine versus placebo in combination with azacitidine in patients…
- Trial name
- NCT06647862
- Testing
- IMM01, Azacitidine
- Where
- 43 sites in China
- Volunteers
- 170 people
- Sponsor
- ImmuneOnco Biopharmaceuticals (Shanghai) Inc.
Accelerated Phase Chronic Myelogenous Leukemia, Adult Acute Lymphoblastic Leukemia in Remission
Fludarabine Phosphate, Low-Dose Total Body Irradiation, and Donor Stem Cell Transplant in Treating Patients With Hematologic Malignancies or Kidney Cancer
This clinical trial studies fludarabine phosphate, low-dose total body irradiation, and donor stem cell transplant in treating patients with hematologic malignancies or kidney cancer.
- Conditions
- Accelerated Phase Chronic Myelogenous Leukemia, Adult Acute Lymphoblastic Leukemia in Remission, Adult Acute Myeloid Leukemia in Remission, Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities
- Trial name
- NCT00005799
- Testing
- fludarabine phosphate, total-body irradiation, nonmyeloablative allogeneic hematopoietic stem cell transplantation
- Where
- 7 sites in United States, Germany
- Volunteers
- 55 people
- Sponsor
- Fred Hutchinson Cancer Center
Malignant Pleural Effusions (Mpe)
A Phase Ib Study of JMKX000197 Injection in the Treatment of Malignant Pleural Effusion
A Phase Ib Study to Evaluate the Safety, Tolerance, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy of JMKX000197 Injection in the Treatment of Malignant Pleural Effusion
- Trial name
- NCT06740019
- Testing
- JMKX000197, Tube thoracostomy drainage
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Jemincare
Non-expandable Lung, Trapped Lung
ARMSTRONG - Air entRainMent vS sTandard tReatment in nOn-expandable luNG
This is a randomised controlled trial evaluating whether controlled air introduction into pleural space (air entrainment) during pleural effusion drainage reduces pain, improves patient satisfaction, and facilitates more…
- Conditions
- Non-expandable Lung, Trapped Lung, Pleural Effusion, Malignant Pleural Effusions (Mpe)
- Trial name
- ARMSTRONG (NCT06959719)
- Testing
- Air Entrainment - intentional introduction of the atmospheric air into the pleural space.
- Where
- United Kingdom
- Volunteers
- 41 people
- Sponsor
- Cambridge University Hospitals NHS Foundation Trust
Myelofibrosis
A Study of Oral Nuvisertib (TP-3654) in Patients With Myelofibrosis
This study is a Phase 1/2, multicenter, dose-escalation, open-label trial to assess safety, tolerability, pharmacokinetics and pharmacodynamics of nuvisertib (TP-3654) in patients with intermediate or high-risk primary or…
- Trial name
- NCT04176198
- Testing
- Nusivertib, Ruxolitinib, Momelotinib
- Where
- 91 sites in United States, Australia and 8 more
- Volunteers
- 240 people
- Sponsor
- Sumitomo Pharma America, Inc.
Polycythemia Vera
Dasatinib in Polycythemia Vera
The purpose for conducting this research study is to determine the feasibility of using dasatinib as a treatment for polycythemia vera and to determine the optimum treatment regimen.
- Trial name
- NCT00538980
- Testing
- Dasatinib
- Where
- 4 sites in United States
- Volunteers
- 10 people
- Sponsor
- Weill Medical College of Cornell University
Leukemia, Lymphoma
Cyclophosphamide Plus Bone Marrow Transplantation in Treating Patients With Hematologic Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Bone marrow transplantation may be able to replace immune cells that were destroyed by chemotherapy or…
- Conditions
- Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm, Myelodysplastic Syndromes
- Trial name
- NCT00006042
- Testing
- filgrastim, cyclophosphamide, fludarabine phosphate
- Where
- United States
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Cancer
Immunotherapy in Treating Patients Who Are Undergoing Bone Marrow or Peripheral Stem Cell Transplantation
RATIONALE: White blood cells from donors who have been exposed to cytomegalovirus may be able to help prevent this infection from occurring in patients who are undergoing bone marrow or peripheral stem cell transplantation.
- Trial name
- NCT00002673
- Testing
- infection prophylaxis and management
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- Fred Hutchinson Cancer Center
Chronic Myeloid Leukemia
Treatment-free Remission After Achieving Sustained MR4.5 on Nilotinib (ENESTop)
A clinical research study to find out if it is safe to stop the drug nilotinib (Tasigna) in chronic myeloid leukemia (CML) patients.
- Trial name
- ENESTop (NCT01698905)
- Testing
- nilotinib
- Where
- 62 sites in United States, Argentina and 16 more
- Volunteers
- 163 people
- Sponsor
- Novartis Pharmaceuticals
Essential Thrombocythemia (ET), Myelofibrosis (MF)
Unraveling the Role of Extracellular Vesicles-driven Senescence in Myeloproliferative Neoplasms
In this study the aim is to investigate the pathogenetic role of extracellular vesicles and senescence in Myeloproliferative Neoplasms.
- Conditions
- Essential Thrombocythemia (ET), Myelofibrosis (MF), Polycythemia Vera (PV)
- Trial name
- NCT06798805
- Where
- 5 sites in Italy
- Volunteers
- 110 people, healthy volunteers welcome
- Sponsor
- IRCCS Azienda Ospedaliero-Universitaria di Bologna
Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia
Adding Itacitinib to Cyclophosphamide and Tacrolimus for the Prevention of Graft Versus Host Disease in Patients Undergoing Hematopoietic Stem Cell Transplants
This clinical trial evaluates the safety and effectiveness of adding itacitinib to cyclophosphamide and tacrolimus for the prevention of graft versus host disease (GVHD) in patients undergoing hematopoietic stem cell transplant.
- Conditions
- Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia, Chronic Myelomonocytic Leukemia, Myelodysplastic Syndrome
- Trial name
- NCT05364762
- Testing
- Cyclophosphamide, Itacitinib, Peripheral Blood Stem Cell Transplantation
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- City of Hope Medical Center
Acute Myeloid Leukemia, Myelodysplastic Syndromes
Dasatinib as Therapy for Myeloproliferative Disorders (MPDs)
The goal of this clinical research study is to learn if dasatinib can help to control myeloproliferative disorders. The safety and tolerability of dasatinib will also be studied.
- Conditions
- Acute Myeloid Leukemia, Myelodysplastic Syndromes, Agnogenic Myeloid Metaplasia, Myelofibrosis
- Trial name
- NCT00255346
- Testing
- Dasatinib (BMS-354825)
- Where
- United States
- Volunteers
- 68 people
- Sponsor
- M.D. Anderson Cancer Center
Chronic Myelogenous Leukemia
Phase II Trial of Decitabine in Patients With Chronic Myelogenous Leukemia Blast Phase Who Are Refractory to Imatinib Mesylate (Gleevec)
To determine the safety and efficacy of decitabine in patients with Philadelphia chromosome-positive chronic myelogenous leukemia blastic phase that were previously treated with imatinib mesylate (STI 571) and became…
- Trial name
- NCT00042003
- Testing
- decitabine (5-aza-2'deoxycytidine)
- Where
- 8 sites in United States, Canada
- Volunteers
- 40 people
- Sponsor
- Astex Pharmaceuticals, Inc.
Primary Myelofibrosis (PMF), Post-polycythemia Vera Myelofibrosis (PPV-MF)
A Phase 3 Study of Pelabresib (DAK539) and Ruxolitinib in Myelofibrosis (MF)
The purpose of this trial is to evaluate whether treatment with pelabresib in combination with ruxolitinib leads to improved clinical outcomes compared to ruxolitinib alone in patients with primary myelofibrosis (PMF)…
- Conditions
- Primary Myelofibrosis (PMF), Post-polycythemia Vera Myelofibrosis (PPV-MF), Post-essential Thrombocythemia Myelofibrosis (PET-MF)
- Trial name
- MANIFEST-3 (NCT07357727)
- Testing
- Pelabresib, Ruxolitinib
- Where
- 159 sites in United States, Argentina and 20 more
- Volunteers
- 460 people
- Sponsor
- Novartis Pharmaceuticals
Myelofibrosis, Primary Myelofibrosis
To Evaluate the Efficacy and Safety of Parsaclisib and Ruxolitinib in Participants With Myelofibrosis (LIMBER-313)
The purpose of the study is to compare the efficacy of parsaclisib when combined with ruxolitinb versus placebo combined with ruxolitinib in participants with myelofibrosis.
- Conditions
- Myelofibrosis, Primary Myelofibrosis, Post Essential Thrombocythemia Myelofibrosis, Post Polycythemia Vera Myelofibrosis
- Trial name
- NCT04551066
- Testing
- parsaclisib, ruxolitinib
- Where
- 177 sites in United States, Austria and 15 more
- Volunteers
- 252 people
- Sponsor
- Incyte Corporation
Acute Leukemia, Myelodysplastic Syndromes
Predictive Clinical and Biological Parameters in Acute Leukemia, Myelodysplastic Syndromes and Myeloproliferative Disorders-HEMATO-BIO-IPC-2013-015
HEMATO-BIO-IPC-2013-015 is a monocenter prospective longitudinal study. Our aim is to define predictive clinical and biological factors in acute leukemia, myelodysplastic syndromes and myeloproliferative disorders by using…
- Conditions
- Acute Leukemia, Myelodysplastic Syndromes, Myeloproliferative Disorders
- Trial name
- HEMATO-BIO (NCT02320656)
- Testing
- Blood sampling, Bone marrow aspirate, Skin biopsy
- Where
- France
- Volunteers
- 650 people
- Sponsor
- Institut Paoli-Calmettes
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.